Volume 21 Issue 12 December 2010
REVIEWS
Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
A. Chan, D. W. Miles, and X. Pivot
Ann Oncol
(2010)1(12):2305-2315 first published online March 24, 2010[Abstract]
Aprepitant: drug–drug interactions in perspective
M. S. Aapro and C. M. Walko
Ann Oncol (2010) 21(12): 2316-2323 [Abstract]
Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
J. C. Soria, C. Massard, and T. Le Chevalier
Ann Oncol (2010) 21(12): 2324-2332
[Abstract]
ORIGINAL ARTICLES
Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1)
S. Ohno, Y. Rai, H. Iwata, N. Yamamoto, M. Yoshida, H. Iwase, N. Masuda, S. Nakamura, H. Taniguchi, S. Kamigaki, and S. Noguchi
Ann Oncol (2010) 21(12): 2342-2347 first published online May 21, 2010 doi:10.1093/annonc/mdq249 [Abstract]
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum–paclitaxel-based chemotherapy, the GINECO experience
J. Alexandre, I. Ray-Coquard, F. Selle, A. Floquet, P. Cottu, B. Weber, C. Falandry, D. Lebrun, E. Pujade-Lauraine, and for the GINECO
Ann Oncol (2010) 21(12): 2377-2381 first published online May 21, 2010 doi:10.1093/annonc/mdq257 [Abstract]
Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients
M. Ronzoni, M. Manzoni, S. Mariucci, F. Loupakis, S. Brugnatelli, K. Bencardino, B. Rovati, C. Tinelli, A. Falcone, E. Villa, and M. Danova
Ann Oncol (2010) 21(12): 2382-2389 first published online May 23, 2010 doi:10.1093/annonc/mdq261 [Abstract]
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial
V. Hess, S. Pratsch, S. Potthast, L. Lee, R. Winterhalder, L. Widmer, C. Cescato, A. Lohri, L. Jost, P. Stillhart, B. Pestalozzi, and R. Herrmann
Ann Oncol (2010) 21(12): 2390-2395 first published online May 5, 2010 doi:10.1093/annonc/mdq242 [Abstract]
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Fariña-Sarasqueta, G. van Lijnschoten, E. Moerland, G.-J. Creemers, V. E. P. P. Lemmens, H. J. T. Rutten, and A. J. C. van den Brule
Ann Oncol (2010) 21(12): 2396-2402 first published online May 25, 2010 doi:10.1093/annonc/mdq258 [Abstract]
